PMID- 33251072
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201201
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 10
DP  - 2020 Oct 26
TI  - Immediate and Short-Term Outcome of Percutaneous Atrial Septal Defects Closure in 
      Adult Patients.
PG  - e11165
LID - 10.7759/cureus.11165 [doi]
LID - e11165
AB  - Background Atrial septal defect secundum (ASD II) is the commonest of the 
      congenital heart diseases in the adult population and the closure of ASD II 
      causes a significant improvement in hemodynamics and the clinical status of the 
      patient. However, it carries certain risks, especially the development of 
      post-closure pulmonary edema and congestive cardiac failure, which may lead to 
      death. Therefore, this study was designed to share our experience and to evaluate 
      the immediate and short-term outcomes of percutaneous closure of ASD II in adult 
      patients presenting at a tertiary care cardiac center in Karachi, Pakistan. 
      Methodology In this study, we included 30 adult (>/= 40 years) patients who 
      underwent percutaneous ASD II closure at the pediatric cardiology department of 
      the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan, 
      between June 1, 2017, and July 31, 2019. Data for this study were extracted from 
      a prospectively collected departmental database. Extracted data for this study 
      consisted of demographic profile, comorbid conditions, echocardiographic 
      findings, cardiac catheterization data, pre and post six-month 
      electrocardiographic findings, and New York Heart Association (NYHA) Functional 
      Classification (FC). Results Out of 30 adult patients, 18 (60%) were female. The 
      mean age of the patients at the time of ASD closure was 51.43 +/- 7.09 years, 
      ranging between 40 and 67 years. None of the patients had any post-intervention 
      complications. Mean systolic pulmonary artery pressure (SPAP) on cardiac 
      catheterization pre-implantation was 49.8 +/- 16.3 mmHg range was 20-90 mmHg while 
      SPAP immediately after device implantation was 37 +/- 11.4 range 20 to 65 mmHg with 
      p<0.001. Mean SPAP on pre-catheterization echocardiography was 58.8 +/- 14.3, range 
      30-95 mmHg, while after six months, the mean SPAP was 34.5 +/- 7.2, range 20-45 
      mmHg, with p<0.001 in 28 (93.3%) patients (in two patients, there was no TR). 
      There was no mortality up till six months after the intervention. The functional 
      class (FC) after six months of the procedure improved in most, 90% (27), of the 
      patients. Conclusion There were no complications immediately after the procedure. 
      After six months, post-procedure SPAP decreased to < 50 mmHg in the majority of 
      patients (96.6%). Functional class (FC) improved in most (90%) of the adult (>/= 40 
      years) patients undergone percutaneous atrial septal defects closure. Therefore, 
      percutaneous closure of ASD II is a safe and effective procedure for adult 
      patients.
CI  - Copyright (c) 2020, Khan et al.
FAU - Khan, Muhammad A
AU  - Khan MA
AD  - Paediatric Cardiology, National Institute of Cardiovascular Diseases, Karachi, 
      PAK.
FAU - Korejo, Hussain
AU  - Korejo H
AD  - Paediatric Cardiology, National Institute of Cardiovascular Diseases, Karachi, 
      PAK.
FAU - Sohail, Arshad
AU  - Sohail A
AD  - Paediatric Cardiology, Rehman Medical Institute, Peshawar, PAK.
FAU - Shaikh, Abdul S
AU  - Shaikh AS
AD  - Paediatric Cardiology, National Institute of Cardiovascular Diseases, Karachi, 
      PAK.
FAU - Patel, Najma
AU  - Patel N
AD  - Paediatric Cardiology, National Institute of Cardiovascular Diseases, Karachi, 
      PAK.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7688064
OTO - NOTNLM
OT  - adult
OT  - atrial septal defect secundum
OT  - congenital heart defects
OT  - percutaneous atrial septal defects closure
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/12/01 06:00
MHDA- 2020/12/01 06:01
PMCR- 2020/10/26
CRDT- 2020/11/30 05:54
PHST- 2020/11/30 05:54 [entrez]
PHST- 2020/12/01 06:00 [pubmed]
PHST- 2020/12/01 06:01 [medline]
PHST- 2020/10/26 00:00 [pmc-release]
AID - 10.7759/cureus.11165 [doi]
PST - epublish
SO  - Cureus. 2020 Oct 26;12(10):e11165. doi: 10.7759/cureus.11165.